Rovida Advisors Inc. Invests $16.15 Million in ASP Isotopes Inc. $ASPI

Rovida Advisors Inc. bought a new stake in ASP Isotopes Inc. (NASDAQ:ASPI) during the second quarter, HoldingsChannel reports. The firm bought 2,200,000 shares of the company’s stock, valued at approximately $16,148,000. ASP Isotopes accounts for approximately 2.5% of Rovida Advisors Inc.’s investment portfolio, making the stock its 9th largest position.

Other large investors have also modified their holdings of the company. Rovida Investment Management Ltd grew its stake in ASP Isotopes by 528.6% in the second quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company’s stock worth $16,148,000 after purchasing an additional 1,850,000 shares in the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of ASP Isotopes in the 2nd quarter worth approximately $9,593,000. Philadelphia Financial Management of San Francisco LLC increased its holdings in shares of ASP Isotopes by 11.2% in the 1st quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company’s stock valued at $16,453,000 after acquiring an additional 354,517 shares during the last quarter. AWM Investment Company Inc. raised its position in shares of ASP Isotopes by 6.2% during the 1st quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company’s stock valued at $21,157,000 after acquiring an additional 265,000 shares in the last quarter. Finally, Creative Planning bought a new position in ASP Isotopes during the second quarter worth $1,272,000. Institutional investors own 16.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ASPI shares. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a research note on Monday, October 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Wednesday, September 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ASP Isotopes in a research report on Thursday, October 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.00.

Insider Activity

In other ASP Isotopes news, Director Todd Wider sold 74,108 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $8.76, for a total value of $649,186.08. Following the completion of the transaction, the director directly owned 710,230 shares of the company’s stock, valued at approximately $6,221,614.80. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert Ainscow sold 67,500 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $7.51, for a total value of $506,925.00. Following the completion of the sale, the chief executive officer owned 1,579,693 shares of the company’s stock, valued at $11,863,494.43. This trade represents a 4.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 473,699 shares of company stock valued at $4,225,902. Company insiders own 21.40% of the company’s stock.

ASP Isotopes Trading Down 1.7%

Shares of NASDAQ ASPI opened at $7.50 on Thursday. The company’s 50 day simple moving average is $9.60 and its 200 day simple moving average is $8.79. The firm has a market capitalization of $700.58 million, a P/E ratio of -5.91 and a beta of 3.28. The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56. ASP Isotopes Inc. has a fifty-two week low of $3.65 and a fifty-two week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last issued its earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. On average, analysts predict that ASP Isotopes Inc. will post -0.24 EPS for the current year.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.